Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.